The global uveitis treatment market is projected to exhibit a significant growth, at a CAGR of around 6.1%, during the forecast period. The increasing prevalence of uveitis with the rising autoimmune disorders and eye-related disorders has been offering growth to the uveitis treatment market. The growing government initiatives to aware population and provide better healthcare facilities are further creating enormous growth opportunities for the uveitis treatment market in the emerging nations, such as India and China. In addition, the increasing healthcare expenditure and growing medical industry will escalate the market growth during the forecast period. An increasing number of hospitals and ophthalmic clinics in emerging economies are providing immense growth opportunities for the uveitis treatment market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uveitis-treatment-market
Such factors have further propelled the need for advanced treatment solutions for uveitis. A new journey can be expected in the uveitis treatment market with the introduction of the novel delivery systems across the globe. This includes the introduction of Iontophoresis for the treatment of anterior uveitis. Iontophoresis refers to the use of an electric current, to propel molecules over the hydrophilic cornea epithelium, which is one of the largest roadblocks to drug penetration in an eye. This expectedly increase the bioavailability of medications, such as steroids, allowing greater reduction in the frequency doses and increase in efficiency, when compared to topical corticosteroids.
Moreover, in May 2018, Clearside Biomedical Inc. introduced novel drug therapy for the treatment of back-of-the-eye diseases. The company announced the attainment for the positive topline results from its new Phase 3 clinical trial of suprachoroidal CLS-TA in patients dealing with macular edema associated with non-infectious uveitis. As per the survey, nearly 47% of patients who were given suprachoroidal CLS-TA for around 12 weeks continuously have gained around 15 letters in best corrected visual acuity (“BCVA”), as measured using the Early Treatment of Diabetic Retinopathy Study (“ETDRS”) scale. Moreover, the trial was well tolerated, with no report of any kind of the serious adverse events during the trial.
Intravitreal Sirolimus is another treatment solution available for the uveitis. It is an immunomodulating agent that reduces the number of T-cells and inflammatory cytokines in the patient’s body. Oral sirolimus is widely used for the treatment of posterior uveitis; however, due to its certain side effects, the physicians do not recommend. There is an ongoing phase 3 study for the investigation of intravitreal sirolimus for the treatment of non-infectious posterior uveitis treatment. In addition, the intravitreal sirolimus has a lower rate of side effects as compared to intravitreal corticosteroids. Such development in the uveitis treatment solutions will drive the market growth during the forecast period.
Global Uveitis Treatment Market-Segmentation
By Disease Type
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Pan Uveitis
By Treatment Type
- Corticosteroids
- Immunosuppressant
- Monoclonal Antibodies
- Cycloplegic Agents
- Others (Antiviral and Antibiotics)
A full report of Uveitis Treatment Market is available at: https://www.omrglobal.com/industry-reports/uveitis-treatment-market
Global Uveitis Treatment Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AbbVie Inc.
- Aldeyra Therapeutics, Inc.
- Alimera Sciences, Inc.
- Allergan PLC
- Bausch Health Companies Inc.
- Cadila Pharmaceuticals Ltd.
- Clearside Biomedical, Inc.
- EyePoint Pharmaceuticals, Inc.
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Prometheus Laboratories Inc.
- Santen Pharmaceutical Co., Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research